American Medical Association is Reviewing Cardio Diagnostics Holdings, Inc's Integrated Epigenetic-Genetic Cardiovascular Medicine Tests For CPT PLA Codes
Portfolio Pulse from Benzinga Newsdesk
The American Medical Association (AMA) is currently reviewing Cardio Diagnostics Holdings, Inc's integrated epigenetic-genetic tests for cardiovascular medicine to determine if they meet the criteria for Current Procedural Terminology (CPT) Proprietary Laboratory Analyses (PLA) codes. These codes are crucial for standardizing billing for lab tests and can significantly impact the reimbursement and adoption rates of new medical technologies.
November 28, 2023 | 1:34 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cardio Diagnostics Holdings, Inc's cardiovascular tests are under AMA review for CPT PLA codes, which could enhance billing processes and adoption if approved.
The AMA's review of Cardio Diagnostics Holdings' tests is a significant step towards potential market adoption and revenue generation. If the tests receive CPT PLA codes, it would likely lead to increased billing standardization and potentially higher reimbursement rates, which could positively impact the company's financial performance in the short term.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 90